Journal issues > Issue 7, November 2016 > Considerations on the use of low molecular weight heparins in patients with cancer and chronic kidney disease

Considerations on the use of low molecular weight heparins in patients with cancer and chronic kidney disease

By: J-M. Hougardy , S. Motte

(BELG J MED ONCOL 2016;10(7):240–242)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top